UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia

Manylion Llyfryddiaeth
Prif Awduron:	Vora, A, Mitchell, C, Goulden, N, Richards, S
Fformat:	Conference item
Cyhoeddwyd:	2010

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
gan: Vora, A, et al.
Cyhoeddwyd: (2010)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
gan: Vora, A, et al.
Cyhoeddwyd: (2013)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
gan: Vora, A, et al.
Cyhoeddwyd: (2013)

UKALL 2003, A Randomised Trial Investigating Treatment Intensification for Children and Young Adults with Minimal Residual Disease Defined High Risk Acute Lymphoblastic Leukaema
gan: Vora, A, et al.
Cyhoeddwyd: (2012)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
gan: Vora, A, et al.
Cyhoeddwyd: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial
gan: Vora, A, et al.
Cyhoeddwyd: (2014)

Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
gan: Vora, A, et al.
Cyhoeddwyd: (2008)

Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
gan: Vora, A, et al.
Cyhoeddwyd: (2008)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
gan: Samarasinghe, S, et al.
Cyhoeddwyd: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
gan: Samarasinghe, S, et al.
Cyhoeddwyd: (2013)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
gan: Patrick, K, et al.
Cyhoeddwyd: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
gan: Patrick, K, et al.
Cyhoeddwyd: (2014)

PROSPECTIVE EVALUATION OF QUALITY OF LIFE (QOL) IN CHILDREN TREATED IN UKALL 2003 FOR ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL): A COHORT STUDY
gan: Eiser, C, et al.
Cyhoeddwyd: (2012)

Prospective evaluation of quality of life in children treated in UKALL 2003 for Acute Lymphoblastic Leukaemia (ALL): A cohort study
gan: Eiser, C, et al.
Cyhoeddwyd: (2017)

Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens Results of the Medical Research Council Trial UKALL2003.
gan: Cutting, R, et al.
Cyhoeddwyd: (2008)

Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: update of results of the Medical Research Council Trial UKALL2003
gan: Cutting, R, et al.
Cyhoeddwyd: (2009)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL)
gan: Moorman, A, et al.
Cyhoeddwyd: (2008)

Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
gan: Qureshi, A, et al.
Cyhoeddwyd: (2010)

Characteristics and outcome of children and young adults with Early T-Precursor (ETP) ALL treated on UKALL 2003
gan: Patrick, K, et al.
Cyhoeddwyd: (2013)

Outcome of Thrombosis in UKALL 2003-Anticoagulation and Re-Exposure to Aspariginase Is Feasible and Safe.
gan: Qureshi, A, et al.
Cyhoeddwyd: (2008)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MRD) clearance in childhood acute lymphoblastic leukaemia (ALL)
gan: Moorman, A, et al.
Cyhoeddwyd: (2007)

Down Syndrome is a significant risk factor for infectious deaths in childhood acute lymphoblastic leukaemia: a retrospective analysis of the infectious deaths on UKALL 2003
gan: O'Connor, D, et al.
Cyhoeddwyd: (2014)

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
gan: O'Connor, D, et al.
Cyhoeddwyd: (2014)

Incidence and Outcome of Osteonecrosis in Children and Young Adults with Acute Lymphoblastic Leukaemia Treated on a Dexamethasone Containing Protocol: Results of the Medical Research Council UK Trial ALL 2003
gan: Vora, A, et al.
Cyhoeddwyd: (2008)

Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
gan: Hann, I, et al.
Cyhoeddwyd: (2000)

UKALL XI randomised trial stratified CNS treatments and prospective neuropsychological assessment in childhood acute lymphoblastic leukaemia (ALL).
gan: Hill, F, et al.
Cyhoeddwyd: (2000)

Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials.
gan: Chessells, J, et al.
Cyhoeddwyd: (1995)

Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.
gan: Jenkinson, S, et al.
Cyhoeddwyd: (2013)

Variables affecting kinetics of minimal residual disease clearance in children with lymphoblastic leukaemia; Results of the United Kingdom Medical Research Council (UK MRC) protocols ALL97, ALL97/99 and ALL2003.
gan: Vora, A, et al.
Cyhoeddwyd: (2005)

High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis.
gan: Patel, B, et al.
Cyhoeddwyd: (2008)

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.
gan: Patel, B, et al.
Cyhoeddwyd: (2010)

Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
gan: Chessels, J, et al.
Cyhoeddwyd: (1997)

Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X.
gan: Wheeler, K, et al.
Cyhoeddwyd: (1996)

Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
gan: Chessells, J, et al.
Cyhoeddwyd: (1997)

Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia.
gan: Chessells, J, et al.
Cyhoeddwyd: (1994)

No association of HLA-A supertype with outcome in childhood acute lymphoblastic leukaemia: results of the UKALL XI trial.
gan: Thompson, P, et al.
Cyhoeddwyd: (2011)

Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALL X.
gan: Chessells, J, et al.
Cyhoeddwyd: (1992)

Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI).
gan: Hargrave, DR, et al.
Cyhoeddwyd: (2001)

Influence of HLA-DP supertype on the survival of childhood acute lymphoblastic leukaemia: analysis of the UKALL X1 trial
gan: Taylor, G, et al.
Cyhoeddwyd: (2008)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia

Eitemau Tebyg

Eitemau Tebyg